No abstract

p<0.001) and 45% lower probability of death (HR¼0.549, 95%CI 0.445-0.678, p<0.001) as compared to those with ALI<18, independent of Performance Status, stage at diagnosis, line of treatment and level of PD-L1 expression. There was no statistically significant correlation of ALI with objective response rates to immunotherapy (PD vs CR or PR or SD, p¼0.623).Conclusions: ALI score correlates with clinical benefit from immunotherapy in advanced NSCLC independent from significant co-variables and may assist decisionmaking in clinical practice. Further validation of its value as a predictive marker of immunotherapy efficacy is ongoing.Legal entity responsible for the study: The authors.